Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

FDA approves cinqair for severe asthma
FDA approves cinqair for severe asthma
Cinqair (reslizumab) has been approved by the U.
Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute
Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute
A federal jury on Thursday ordered Gilead Sciences Inc (GILD.
Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
TARRYTOWN, N.
NICE backs use of Johnson & Johnson's prostate cancer drug Zytiga
NICE backs use of Johnson & Johnson's prostate cancer drug Zytiga
The National Institute for Health and Care Excellence issued final draft guidance Monday recommending NHS reimbursement of Johnson & Johnson's Zytiga (abiraterone) for certain patients...
Profectus, Vyriad to develop oncolytic rVSV vaccines to treat cancer
Profectus, Vyriad to develop oncolytic rVSV vaccines to treat cancer
Profectus BioSciences and Vyriad have entered into a collaboration to develop oncolytic recombinant vesicular stomatitis virus (rVSV) vaccines for cancer immunotherapy.
Teva Launches Generic Campral In U.S.
Teva Launches Generic Campral In U.S.
Teva Pharmaceutical Industries Ltd.
Drug combination shows benefit for men with melanoma
Drug combination shows benefit for men with melanoma
WASHINGTON, March 18 (UPI) -- A drug combination approved last year by the U.
Fangs giving: How snake venom could hold the key to Alzheimer's treatment
Fangs giving: How snake venom could hold the key to Alzheimer's treatment
Melbourne researchers believe snake venom may hold the key to destroying plaques that cause Alzheimer's disease, offering new hope for a drug that could prevent the disease taking hold in newly-di...
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
THOUSAND OAKS, Calif.
Pfizer's Xeljanz rheumatoid arthritis drug meets endpoints in ulcerative colitis trials
Pfizer's Xeljanz rheumatoid arthritis drug meets endpoints in ulcerative colitis trials
Pfizer's rheumatoid arthritis drug Xeljanz (tofacitinib) has met primary and key secondary endpoints in two phase trials to treat ulcerative colitis (UC).
Allergan Confirms Generic Abraxane® Patent Challenge
Allergan Confirms Generic Abraxane® Patent Challenge
DUBLIN, March 17, 2016 /PRNewswire/ -- Allergan plc (NYSE.
Express Scripts says U.S. drug spending rose 5.2 percent in 2015
Express Scripts says U.S. drug spending rose 5.2 percent in 2015
U.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand